These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10155313)

  • 21. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses.
    Suh C; Kim HJ; Kim SH; Kim S; Lee SJ; Lee YS; Kim EK; Kim SB; Lee JS; Kim MW; Kim K; Yoon SS
    Transfusion; 2004 Apr; 44(4):533-8. PubMed ID: 15043569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.
    Goa KL; Bryson HM
    Pharmacoeconomics; 1994 Jan; 5(1):56-77. PubMed ID: 10146867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.
    Blaise D; Kuentz M; Fortanier C; Bourhis JH; Milpied N; Sutton L; Jouet JP; Attal M; Bordigoni P; Cahn JY; Boiron JM; Schuller MP; Moatti JP; Michallet M
    J Clin Oncol; 2000 Feb; 18(3):537-46. PubMed ID: 10653869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) and orthotopic liver transplantation for glycogen storage disease type Ib.
    Lachaux A; Boillot O; Stamm D; Canterino I; Dumontet C; Regnier F; Floret D; Hermier M
    J Pediatr; 1993 Dec; 123(6):1005-8. PubMed ID: 7693904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
    Bui BN; Chevallier B; Chevreau C; Krakowski I; Peny AM; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
    J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
    Hüttmann A; Schirsafi K; Seeber S; Bojko P
    J Cancer Res Clin Oncol; 2005 Mar; 131(3):152-6. PubMed ID: 15583936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
    Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
    Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia.
    Juan O; Campos JM; Carañana V; Sanchez JJ; Casañ R; Alberola V
    Support Care Cancer; 2001 Jun; 9(4):241-6. PubMed ID: 11430419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.
    Frampton JE; Faulds D
    Pharmacoeconomics; 1996 Jan; 9(1):76-96. PubMed ID: 10161371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
    Sebban C; Lefranc A; Perrier L; Moreau P; Espinouse D; Schmidt A; Kammoun L; Ghesquieres H; Ferlay C; Bay JO; Lissandre S; Pérol D; Michallet M; Quittet P
    Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia.
    Takeshita A; Saito H; Toyama K; Horiuchi A; Kuriya S; Furusawa S; Tsuruoka N; Takiguchi T; Matsuda T; Utsumi M; Shiku H; Matsui T; Egami K; Tamura K; Ohno R
    Int J Hematol; 2000 Feb; 71(2):136-43. PubMed ID: 10745623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation.
    Souêtre E; Qing W; Pénelaud PF
    Eur J Cancer; 1996 Jun; 32A(7):1162-5. PubMed ID: 8758247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison.
    Toner GC; Shapiro JD; Laidlaw CR; Rischin D; Millward MJ; Wolf M; Januszewicz H; Mitchell SV; Curran AC; Matthews JP; Bishop JF
    J Clin Oncol; 1998 Dec; 16(12):3874-9. PubMed ID: 9850033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
    Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A
    Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
    Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
    J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of molgramostim, filgrastim and lenograstim in the treatment of myelokathexis.
    Cernelc P; Andoljsek D; Mlakar U; Pretnar J; Modic M; Zupan IP; Zver S
    Pflugers Arch; 2000; 440(5 Suppl):R81-2. PubMed ID: 11005621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colony stimulating factors: G-CSFs--filgrastim (Neupogen) and lenograstim (Granocyte).
    MacConnachie AM
    Intensive Crit Care Nurs; 1998 Feb; 14(1):49-50. PubMed ID: 9652261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
    Schmitz N; Dreger P; Zander AR; Ehninger G; Wandt H; Fauser AA; Kolb HJ; Zumsprekel A; Martin A; Hecht T
    Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.